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ABSTRACT
REGULATION OF RECEPTOR TYROSINE KINASES BY UBIQUILIN1
Zimple Kurlawala
June 25, 2015
Receptor Tyrosine Kinases (RTK’s) like EGFR, Insulin Receptor, IGF1R and
others mediate growth, proliferation and balance between apoptosis and survival.
Dysregulation of RTK activity has been identified in a wide range of cancers and
contributes to initiation, progression and metastasis of tumors. Ubiquilins
(UBQLN) are fairly novel proteins and are studied mostly in the field of
neurodegenerative disorders. Our laboratory recently discovered a link between
UBQLN1 function and tumorigenesis. UBQLN1 is lost in about 50% of non-small
cell lung cancer (NSCLC) cases. We have identified an interaction between
UBQLN1 and IGF1R. Furthermore, UBQLN1 regulates activity of IGF1R and
EGFR. Following loss of UBQLN1 in lung adenocarcinoma cells, there is
decreased expression of IGF1R and EGFR at the mRNA and protein levels.
Fewer receptors are available for ligand binding on plasma membrane of
UBQLN1 deficient cells. Despite this decrease in total number of receptors, the
ratio of active:inactive (phosphorylated:non-phosphorylated) receptor is higher in
cells that have loss of UBQLN1 function. We conclude that UBQLN1 is essential
in normal regulation of RTKs. Loss of UBQLN1 leads to persistent stimulation of
IGF1R and EGFR which may contribute to transforming events in UBQLN1
iv

deficient cells. Understanding the role of UBQLN1 in regulating receptor tyrosine
kinase activity can facilitate development of pharmacological drugs targeting
novel

pathways

in

diseases

that

have

v

altered

function

of

UBQLN1.
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CHAPTER 1: INTRODUCTION

Ubiquilins (PLICs)
The Ubiquilin family of proteins (UBQLN1-4, UBQLNL) are evolutionarily
conserved and structurally similar to each other. These proteins are encoded by
genes on different chromosomes: UBQLN1 (9q22, 589 or 561 amino acids),
UBQLN2 (Xp11.21, 624 amino acids), UBQLN3 (11p15, 654 amino acids),
UBQLN4 (1q21, 601 amino acids) and UBQLN-L (11p15.4, 475 amino acids) [1].
Ubiquilins are also known as Proteins Linking IAP with Cytoskeleton (PLICs) as
these were originally discovered as proteins that anchor vimentin filaments to the
plasma

membrane

interaction

with

integrin-associated
(IAP)

[2].

through

CD47,

an

protein

UBQLN1

is

approximately 63 kDa protein
and all its family members
have

3

main

domains:

ubiquitin-like domain (UBL) at
the

N-terminus,

ubiquitin-

Figure 1: Schematic of structural domains
of UBQLN1
UBL domain: UBiquitin-Like domain interacts
with the S5a cap of the proteasome.
STI-1,2,3,4
domains:
STress-Inducible
proteins. These domains act as chaperonins
that mediate protein-protein interactions.
UBA domain: UBiquitin-Associated domain
associates directly with ubiquitin.

associated domain (UBA) at
the C-terminus and STI chaperone-like regions in the middle (Figure 1). UBQLN1
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maintains all the functionally important motifs present in this group [3].
Expression of Ubiquilin varies based on tissue type. UBQLN1 is ubiquitously
expressed in all tissues, UBQLN2 and UBQLN4 show relatively higher
expression in the brain, spleen, heart, liver and pancreas over other tissues,
UBQLN3 is exclusively expressed in the testis [3] and UBQLNL is mostly found in
plasma, platelet and liver.

Proposed Functions
Owing to their structural orientation, Ubiquilins are categorized as ubiquitin
binding proteins (UBPs). UBQLN1 assists in proteasomal degradation of
ubiquitinated substrates and also participates in ERAD (Endoplasmic Reticulum
Associated Degradation), autophagy, apoptosis and receptor trafficking [4]. The
UBL domain of UBQLN is structurally similar to ubiquitin and interacts with the
proteasomal cap (S5a) [5] while the UBA domain associates directly with
ubiquitin [6, 7]. The central region consisting of STI domains are called so
because of their similarity to STI-1 proteins (STress Inducible proteins or Hsp70Hsp90 organizing protein, HOP). This region acts as a co-chaperone and
mediates hydrophobic interactions with other proteins [8, 9]. Together, the UBL
domain of Ubiquilin1 binds to the proteasome while the UBA domain binds to
ubiquitin on the substrate protein and aids in the substrate’s degradation [5].

Several studies have reported that UBQLN1 facilitates proteolysis of substrates
that it binds to. Dsk2p, the yeast homolog of UBQLN1, forms a trimeric complex
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with Rad23p and Cdc48 and enables degradation of misfolded proteins via the
proteasomal system [10]. In human cells, the UBL domain of UBQLN1 has been
shown to regulate degradation of misfolded proteins like Ataxin3, HSJ1a and
EPS15 [11]. UBQLN1 expression aids in poly-ubiquitination of viral polymerase
NS5B, decreasing its half-life in HCV infected hepatocytes [12]. In contrast,
UBQLN1 stabilizes proteins like Presenilin1 and 2 [3, 13], Rad23 [14], IκB [15],
and Bclb [1] when bound to them.
UBQLN1 and UBQLN2 were originally (1999) identified in ovarian cancer cells
and showed to increase cell spreading and integrin mediated interactions with
the extracellular matrix. Identifying functions of Ubiquilin proteins is an ongoing
area of research. UBQLN1 is a stress-response protein; its expression protects
astrocytes from hypoxia [16] and HeLa cells from starvation-induced death [17].
In 2010, Rothenberg et al showed that UBQLN1 interacts with autophagy marker
LC3 in a complex with other proteins and reduction in UBQLN1 expression
decreases autophagy levels in HeLa cells, brain and liver tissue of mice [18].
UBQLN1 is also reported to interact with the metabolite mTOR; however, the
consequences of this interaction are not known [19]. In superior cervical ganglion
neurons, UBQLN1 expression limits the expression of unassembled nicotinic
acetylcholine receptors in the absence of nicotine stimulation [20].

3

Ubiquilin in Neurodegenerative Disorders
Presenilin proteins (PS1 and 2) are well-established Alzheimer’s diseaseassociated proteins [21]. UBQLN1 binds to and stabilizes PS1 and 2 and colocalize in a vesicular-like or ER-like pattern [3, 12]. A meta-analysis in 2014
confirmed that a single intronic C/T polymorphism in UBQLN1 (UBQ-8i)
significantly increased risk of Alzheimer’s disease [22, 23]. In the presence of this
polymorphism, the STI domains of UBQLN1 are unable to bind to PS proteins as
a result of which a gamma secretase complex is formed generating Aβ40 and
Aβ42 amyloid aggregations [13, 24, 25]. Ford et al (2006) hypothesize that UBQ8i polymorphism favors formation of UBQLN dimers and loses its ability to bind to
PS proteins. Neurofibrillary tangles and Lewy bodies in brains of Alzheimer’s
disease and Parkinson’s patients robustly stained for anti-UBQLN antibodies
provide more evidence to the role of UBQLN in these diseases [13].

UBQLN1 is also implicated in pathogenesis of triplet repeat neurodegenerative
diseases especially ones characterized by expanded polyglutamine (PolyQ)
tracts. Of the nine different types of PolyQ diseases, UBQLN1 plays a role in
Huntington’s disease (HD) and spinocerebellar ataxia type1 [26]. The expansion
of glutamine tracts leads to aggregation of the affected protein as it is unable to
get degraded effectively in absence of UBQLN1. In an animal model of
Huntington’s disease, UBQLN4 expression was identified to be protective as it
decreased polyQ-induced protein aggregation though its interaction with Ataxin1
and UBQLN1 [27].

4

UBQLN2 mutations have been identified in X-linked Amyotropic Lateral Sclerosis
(ALS) and Fronto-Temporal Dementia (FTD). UBQLN2-positive inclusions are
detected in spinal cord of ALS patients and in hippocampus of ALS patients with
dementia proposing a role of mutant UBQLN2 aggregation in neurodegeneration
[28].

Ubiquilin in Cancer
First evidence of role of Ubiquilin proteins in cancer development was reported in
1999, when Funakoshi and colleagues found that XDRP1, a Xenopus orthologue
60% similar to Ubiquilin1 interacted with cyclin A, preventing its degradation and
arresting cell division. Another way UBQLN1 has been proposed to regulate cell
division is by binding to a tumor suppressor protein DAN and S(1-5) which
modulates DNA synthesis. In contrast, UBQLN2 expression enhanced tumor
progression in osteosarcoma [29].

Previous work from our lab has identified UBQLN1 as a regulator of antiapoptotic protein Bcl2L10/Bclb [1]. We have reported that UBQLN1 is lost in
about 50% of lung adenocarcinomas and tissue samples have varying UBQLN1
mRNA levels. We have also shown that loss of UBQLN1 or UBQLN2 promotes
epithelial to mesenchymal transition (EMT) in lung adenocarcinoma cell lines [4].
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Receptor

Tyrosine

Kinases (RTK’s)
Receptor

Tyrosine

Kinases are cell surface
proteins that have an Nterminus

extracellular

domain, a transmembrane
domain and a C-terminus
intracellular

domain

possessing

intrinsic

tyrosine

kinase

activity

(Figure

2).

These

Figure 2: Schematic of structural domains of
IGF1R Receptor tyrosine kinases have an
extracellular domain that binds to and is activated
by ligand, a transmembrane domain spanning
across the plasma membrane and an intracellular
domain bearing multiple tyrosine residues that
undergo auto- and trans- phosphorylation. The
above schematic is of the receptor tyrosine kinase
IGF1R that is present on the plasma membrane
as a preformed homodimer held together by
disulfide bonds as shown. Each part of the dimer
consists of the α and β subunits.

receptors are present on the cell surface as preformed dimers as in case of
Insulin-like Growth Factor 1 Receptor (IGF1R) or undergo dimerization upon
ligand binding for example Epidermal Growth Factor Receptor (EGFR). There
are approximately thirteen subfamilies of RTK’s and sixty members in all [30].
Receptor activation occurs upon binding to specific ligands, following which the
receptor gets auto- and trans-phosphorylated at their intracellular domain and
stimulates downstream signaling pathways that mediate growth, proliferation,
survival, tissue homeostasis, and metabolism. Dysregulation of RTK’s have been
identified in a number of cancers and can be responsible for initiation,
progression and metastasis of tumors. Receptor tyrosine kinases like EGFR,
IGF1R, Insulin receptor (INSR), FGFR and non receptor tyrosine kinases like
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SRC, Abl, FAK are upregulated in a wide range of cancers [31]. In normal cells,
the activity of RTK’s is tightly regulated. However, these can become oncogenic
following gain of function mutations, gene rearrangement, gene amplification,
loss of genomic imprinting or abnormal receptor or ligand activation. RTKs like
EGFR and analogues HER2, Erb2; VEGF and VEGFR, IGF1R and others are
major targets of current cancer therapies.

EGFR and IGF1R
The epidermal growth factor receptor family comprises of many subtypes of
receptors: EGFR (ErbB1), ErbB2/HER2/neu, ErbB3/HER3 and ErbB4/HER4.
Ligands of these receptors include EGF, amphiregulin, betacellulin, neuregulins,
and others.Activation of EGFR stimulates growth and proliferative pathways.
Mutations and overexpression of EGFR family of proteins are largely implicated
in lung adenocarcinoma and breast cancers [32].

Insulin-like growth factor 1 receptor (IGF1R), IGF2R and IR (insulin receptor) are
RTKs that are ubiquitously expressed in cells and bind to their ligands IGF1,
IGF2, insulin with differing affinities. Their basic function is to stimulate growth
and survival. IGFBPs (IGF binding proteins 1-6) also bind these ligands and limit
their bioavailability to bind to RTKs [33]. Increased IGF1R expression is found in
a number of cancers, including breast, prostate, colorectal, liver, lung and
melanoma. In a study by Nakagawa et al in 2012, IGF1R expression was
associated with an increased risk of recurrence of non-small cell lung cancer
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(NSCLC). A meta-analysis of 17 studies comprising 3,294 NSCLC patients
concluded that IGF1R expression positively correlated with smoking status,
tumor size and is a negatively correlated with disease free survival [34].
Increased IGF1 levels increase the risk of development of breast, prostate,
colorectal cancers. Normally, cells are dependent on circulating levels of IGF1
produced by the liver but cancer cells show increased IGF1R activity by
producing their own IGF1 through autocrine and paracrine processes. IGF1R
activation

stimulates

PI3K/AKT

(survival)

and

RAS/MAPK

(proliferation)

pathways [35].

IGF1R Structure and Trafficking IGF1R is synthesized as a monomer
consisting of α and β chains. This monomeric pro-receptor undergoes maturation
though proteolysis and glycosylation to form dimers. IGF1 receptors are present
on the the cell surface as preformed dimers unlike EGFR that form dimers upon
ligand binding (Figure 3). The β subunit consists of 627 amino acids, has a small
extracellular portion, transmembrane portion and the intracellular C-terminal. The
juxtamembranous region in the β subunit hosts the NPXY motif and the catalytic
region. The NPXY motif participates in the process of receptor internalization
while the catalytic region is crucial for ATP binding. Tyrosine 1131, 1135 and
1136 in the intracellular tyrosine kinase domains are critical for receptor
autophosphorylation. The intracellular domains hold crucial signals that decide
the fate of receptor trafficking once it is activated. For example, even though
overall there is 70% amino acid homology between IGF1R and Insulin receptor,
there is only 44% homology in their C-terminus sequence which dictates the
8

Figure 3: IGF-1R structure–function relationship. Adapted from Girnita et al,
2014. This map depicts location of amino acid residues in IGF1R and their functions,
their binding partners and posttranslational modifications (PTMs) at these amino acid
residues [36]

differences in downstream signaling pathways and functions between the 2
receptors. The NPXY motif recognizes the phosphotyrosine binding domains
(PTB) of IRS proteins and SH2 proteins (Figure 4). The IRS proteins (IRS 1-4)
undergo full activation within 1-2 mins and Shc protein within 5-10 mins of ligand
binding to IGF1R [36].
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IRS proteins interact with IGF1R on the cell surface through their pleckstrin
homology domains (PH) and PTB domains are present in their N-terminus. The
C-terminus region of IRS proteins are variable and control the variety of
interactions with other signaling molecules. The C-terminal of IRS proteins have
a high affinity for proteins that have an SH2 domain like PI3K, Grb2, SH-PTP2
(phosphatase), adaptor proteins like CRK, NCK1 which act as docking proteins
for interaction of IGF1R with other proteins like β1 integrins on the cell surface.
Like IRS proteins,
SHC proteins (SHC
A-D) also consist of
a PTB domain

at

their N-terminal and
a SH2 domain at
their C-terminal an
interact

with

proteins in a similar
fashion.
domains,

These
their

Figure 4: IGF1R signaling pathways. Adapted from
Girnita et al, 2014. Upon activation by ligand IGF1, there is
phosphorylation of intracellular tyrosine kinase domains of
IGF1R. The activated receptor phosphorylates IRS and
Shc proteins as its first substrates, which further activate
other proteins like GRB2, SOS and so on. Broadly, IGF1R
leads to activation of 2 major kinase cascades - RAS/MAPK
and PI3/AKT pathways [30].

characteristics and
the interactions they are capable of control further trafficking events of the
activated receptor. Internalization of IGF1R is known to occur through clathrin
mediated endocytosis (CME) and also through calveolin mediated endocytosis at
high levels of IGF1 [37]. Internalized RTK’s in early endosomes proceed to late
10

endosomes
continue

and
to

send

signals through their Cterminus

in

the

cytoplasm. In the late
endosome,
either

gets

the

RTK

recycled

back to the plasma
membrane through a
recycling endosome or
gets

degraded

lysosomal

via
or

proteasomal pathways
(Figure 5). Multi-protein
complexes

called

Figure 5: Endocytic Trafficking of RTK
Adapted from Goh & Sorkin [37]. This figure shows
2 pathways of endocytosis of ligand bound RTK:
clathrin mediated and calveolin mediated. The
internalized receptor in clathrin-coated vesicles
(CCV) is transported to the early endosome (EE) to
the sorting endosome (SE) or the mutivescicular
body (MVB) and from here either to the recycle
endosome to be recycled back to the plasma
membrane or degraded in the lysosomal
endosome (LE).

Endosomal Sorting Complex Required for Transport (ESCRT) are critical for
cellular transport of activated receptors [37]. These processes occur by
systematic co-operation of a variety of adaptor proteins and in absence of an
interacting partner can potentially disturb trafficking and alter biological
consequences. Ubiquitin interacting motif (UIM) containing adaptor proteins like
Epsin, Eps15, Eps15R recognize ubiquitin on RTKs, bind to clathrin and AP2
simultaneously and are critical for clathrin mediated endocytosis (CME) of some
RTKs like EGFR (Figure 6). The NPXY motif not only regulates internalization of
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IGF1R

but

also

its

downregulation. All RTKs
possess

a

binding

motif

ubiquitination
well

ubiquitin

has

established

and
been
as

a

crucial regulatory process
of

RTK

trafficking.

Ubiquitin is a small protein
(7 kD) that is added to
IGF1R in 3 consecutive
steps via the E1, E2 and

Figure 6: Schematic of clathrin mediated
endocytosis of EGFR. Adapted from Madshus et al
[38]. Phosphorylated RTK and activates tyrosine

kinases facilitating binding of an E3 ligase Cbl to
the C-terminal of the RTK, or indirectly via an
adaptor protein Grb2. Poly-Ub chains added by
Cbl interact with Ub-interaction motifs (UIMs) of
Epsin-1 and Eps15 which act in co-ordination
with other proteins (not shown) and subsequently
cause invagination of the plasma membrane and
form a clathrin-coated vesicle

E3 ligases. The first two
enzymes, E1 and E2 work to load the last enzyme E3 on to IGF1R to add
ubiquitin molecules on the receptor. IGF1R is a known substrate of three E3
ligases: Mdm2 [38] Nedd4 [39] and c-Cbl [40]. Ubiquitination of IGF1R occurs
before entering the endocytic vessels during internailization [39]. Mdm2 polyubiquitinates IGF1R with K63-type chains and β-arrestins have been identified as
crucial adaptor proteins to recruit Mdm2 to IGF1R [41]. Similarly, Grb10 is a key
adaptor protein that recruits Nedd4 to IGF1R which multi mono-ubiquitnates the
receptor [39]. At higher doses of IGF1, c-Cbl poly-ubiquitinates IGF1R with K48type chains. Mdm2 recruitment favors stimulation of MAPK over PI3K pathways.
Like IGF1R, EGFR is also poly-ubiquitinated with K63-type chains [42]. K48 poly-
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ubiquitination signals target substrates for proteasomal degradation while K63
mono- and poly-ubiquitination are recognized by other proteins through their
ubiquitin binding domains (UBD) and activate enzyme cascades like kinases,
phosphatases, phospholipases and so on that feed into and activate multiple
downstream pathways like PI3K/AKT, RAS/MAPK, metabolic pathways and
others [43, 44]. Ubiquitination is a major molecular signal responsible for
endocytic sorting such that ubiquitination of IGF1R is essential for its
internalization while its not for other RTKs like EGFR and FGFR2. However,
degradation of these 3 RTK’s is highly dependent on their ubiquitin-conjugation
[42, 45, 46].

Aim
To

study

regulation

of

receptor

13

tyrosine

kinases

by

Ubiquilin1.

CHAPTER 2: MATERIALS AND METHODS

Cell culture
Human normal lung epithelial cell line HPL1D and human non-small cell lung
carcinoma cell line A549 and H358 were purchased from American Type Culture
Collection (ATCC, Rockville, MD, USA) and cultured in RPMI medium
supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and
1% antibiotic/antimycotic (Sigma, St Louis, MO, USA). The 3 cell lines were
routinely subcultured every 3–4 days. All siRNA transfections were performed
using Dharmafect1 #T-2001-03 (Thermo Fisher Scientific Inc, Pittsburgh, PA,
USA) as per manufacturer’s protocol. After total 48 hours of transfection, cells
were serum starved for 12 hours. After which IGF1 50ng/ml or 10ng/ml of EGF
was added to stimulate the cells. For protein stability studies, 20uM of
Cycloheximide was added an hour prior to adding IGF1. MG132 (25uM) and
NH4Cl (20uM) were also added an hour prior to adding IGF1 for experiments
investigating route of degradation of RTKs. At the end of stimulation, 6 hours for
IGF1 and 3 hours for EGF, cells were harvested in CHAPS lysis buffer (1%
CHAPS detergent, 150mM NaCl, 50mM Tris pH 7, 5mM EDTA). Protein was
quantitated by using Pierce's BCA Protein Assay Reagent Kit (# 23227) from
Pierce Biotechnology, Rockford, IL, USA as per manufacturer’s protocol.
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Immunoprecipitation and Western Blot Analysis
293T cells were cultured in DMEM supplemented with 10% FBS. DNA
transfections were done using PEI (PEI 2.5:1 DNA).

All cell extracts were

prepared following scrape harvesting of 293T cells using CHAPS lysis buffer (1%
CHAPS detergent, 150 mM NaCl, 50 mM Tris pH 7, 5 mM EDTA), For
immunoprecipitations, 200 ug of protein was incubated in 400 uL of total CHAPS
buffer and incubated with indicated affinity matrix (Anti-FLAG beads) for 1 h at
4 °C. Following incubation, the matrix was washed three times in CHAPS buffer
and then SDS loading buffer was added directly to washed matrix, boiled, and
loaded directly into the wells of a PAGE gel. Drug treatments were performed as
described in the text using 20 uM cycloheximide or 25 uM proteasome inhibitor
MG132.

Immunofluorescence Staining
Cells were dry seeded in 35 mm IF plates culture and transfected with either non
targeting siRNA (siNT) or with siRNAs targeting UBQLN1 (siU1 and siU1-2) the
following day. After 48 hrs of transfection, cells were fixed with 4.0%
paraformaldehyde in PBS for 15-20 min and then permeabilized with 0.1%
Saponin for 60 minutes at room temperature. Cells were rinsed thrice with PBS,
and then incubated overnight with anti-UBQLN1 or anti-IGF1R antibody (at a
dilution of 1:1000). Next day, after three successive washes with PBS, cells were
then incubated with Alexa Fluor 488 goat anti-rabbit IgG (A11034: Molecular
Probes, Invitrogen detection technologies, Eugene, OR, USA) at a dilution of
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1:1000. After incubation with secondary antibody for 60 minutes, cells were
rinsed with PBS and incubated with Alexa Fluor 568 Phalloidin (A12380: Life
technologies Eugene, OR, USA) for 10 minutes at the dilution of 1:1000. After 3
successive washes with PBS, nuclei were counterstained with DAPI (diluted
1:000) for 10 min at room temperature followed by three washes (5–10 min each)
with PBS. The cells were then imaged under Nikon A1R confocal laser scanning
microscope. Multiple images were acquired from multiple experiments and
representative images are presented.

Radioligand Binding
Cells were incubated for 2 hours with increasing concentrations (0.001 nM to
0.05 nM) of

125

I-IGF1 (Perkin Elmer, Waltham, MA) at 4°C in binding buffer

(DMEM/20 mM HEPES/0.1% BSA, pH 7.3). Two fractions were collected – total
ligand binding (125I-IGF1) and non-specific binding (mixture of radiolabeled and
non-radiolabeled ligand). After 2 hours incubation on ice, cells were washed four
times with binding buffer to remove unbound radioligand. Solubilizing buffer
(0.5N SDS, 1N NaCl) was used to collect the cells and the radioactivity of each
fraction was determined using a Beckman Coulter (Brea, CA) gamma counter.
Specific binding for each concentration of

125

I-IGF1 was calculated by subtracting

non-specific binding from total binding for that concentration of
Scatchard graphs were plotted to determine Kd and Bmax.
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125

I-IGF1.

Total RNA Extraction and Real Time PCR
Total RNA was isolated from the A549 cells after washing twice with phosphatebuffered saline (PBS) and harvested with E.Z.N.A Total RNA Extraction Kit
(Omega, USA) according to the supplier’s protocol followed by DNAse digestion.
RNA quality and quantity were determined by photometry. Total RNA (1μg) was
reverse-transcribed to cDNA using Thermo Script RT–PCR kit. Briefly, RNA was
reverse-transcribed in cDNA with oligo (dT) primers and 200 U of Superscript II
(Invitrogen) following manufacturer’s instructions. Real-time analysis for IGF1R,
EGFR, and normalizing gene human β2Microglobulin was performed using
SYBR Green Master Mix as per the manufacturer’s instruction (Applied
Biosytems).

This

technique

continuously

monitors

the

cycle-by-cycle

accumulation of fluorescently labeled PCR product. Briefly, cDNA corresponding
to 25 ng of RNA served as a template in a 10μl reaction mixture containing,
0.2 nM (each) primer, and 5 μl FastStart DNA Master SYBR Green mix (ABI).
Samples were loaded into 96-well plate format and incubated in the fluorescence
thermocycler 7500 (ABI System). Initial denaturation at 95 °C for 10 min was
followed by 45 cycles, each cycle consisting of 95 °C for 15 s, touchdown of
1 °C/cycle from the primer-specific start to end annealing temperatures for
5 seconds, and 60 °C for 10 seconds. The primer sequences used for specific
genes are listed in Table. All quantifications were normalized to the
housekeeping HPRT gene, which showed a very stable expression in A549 cells.
Fold changes in gene expression were calculated using 2−ΔΔCT method. Following
are the primer sequences used for the reaction:
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IGF1R

F: GCCAAGCTAAACCGGCTAA
R: TATCCTCTTTTGGCCTGGACATA

EGFR

F: GGCTCTGGAGGAAAAGAAAGTTT
R: CACCTCACAGTTATTGAACATCCTCT

hβ2Microglobulin

F: TGACTTTGTCACAGCCCAAGATA
R: AATGCGGCATCTTCAAACCT

Statistical analysis
All data were analyzed Differences between two groups were statistically
analyzed using unpaired Student's t-test. Differences were considered significant
when p<0.05.

Reagents
IGF1R-beta #3027, IGF1R Beta XP #9750, p-IGF1R beta #3918, EGFR #2232,
p-EGFR #2304, AKT #9272, p-AKT #9271 (Cell Signaling Technologies Inc.
Danvers, MA 01923); Tubulin #B512 (Sigma); GAPDH #FL335 (Santa Cruz);
Ubiquilin polyclonal Ab was made by inoculating rabbits with a peptide specific to
Ubqln1 (Yenzym Antibodies LLC); Alexa Fluor 488 goat anti-rabbit IgG #A11034
(Molecular Probes, Invitrogen detection technologies, Eugene, OR. USA); Alexa
Fluor 568 Phalloidin #A12380 (Life technologies Eugene, OR. USA); Anti-FLAG
Affinity Gel (Sigma A2220).
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RNAi Sequences
All RNAi (siRNAs) used for study were ordered from Thermo Fisher Scientific
Biosciences Inc. Lafayette, CO 80026, USA and transfections were done using
Dharmafect1 as per the suppliers instructions.
NonTargeting

siNT

UAAGGCUAUGAAGAGAUACAA

Ubiquilin1

siUBQLN1
siUBQLN1-2

GAAGAAAUCUCUAAACGUUUUUU
GUACUACUGCGCCAAAUUU
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CHAPTER 3: RESULTS
UBQLN1 is lost and under-expressed in cancers (Previous work) (Figure 7)
Previously, our lab has shown that UBQLN1 is lost, mutated and under expressed in human cancers. We analyzed 877 cancer cell lines from
the Cancer Cell Line Encyclopedia and found that 243 (27.7%) had loss
or

deletion

of

UBQLN1.

Furthermore,

these

cancer

c ell

lines

demonstrated significantly lower expression of UBQLN1 ( P<0.0001)
than those without loss or deletion suggesting that copy number
alteration is a mechanism of UBQLN1 inactivation in cancer cells.
Similarly, examination of 230 lung adenocarcinoma t umors from the
Cancer Genome Atlas revealed a high frequency of copy number loss
(50.8%) with a corresponding significant decrease in gene expression
levels (P<0.001)[4]. Our lab has identified 343 genes by microarray
analyses that are expressed differently between tumors with h igh or
low levels of UBQLN1. By Ingenuity pathway analysis, we found that
UBQLN1 played a major role in proteins associated with molecular
transport and protein trafficking. Among these are proteins involved in
signaling pathways like MYC and AKT signaling and other proteins
involved

in

cell

cycle
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regulation

[1].

Figure 7: Ubiquilin1 is lost and under-expressed in cancers [4]
UBQLN1 is frequently lost and under-expressed in cancer cell lines. Cancer
cell lines are separated by UBQLN1 copy number status and their
corresponding UBQLN1 expression plotted. Box plots depict the median
group expression (middle line), the 25th and 75th percentiles (bottom and
top of box, respectively), with the whiskers indicating the 10th and 90th
percentiles. Values for all samples outside this range are represented by
dots. The UBQLN1 locus is lost in 243 of the 877 cell lines examined.
UBQLN1 is significantly under-expressed in samples with UBQLN1 loss or
deletion (P<0.0001, Mann–Whitney U-test).
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UBQLN1 interacts with IGF1R and INSR (Figure 8)
To detect potential interacting partners of UBQLN1, we over-expressed FLAG
epitope-tagged

UBQLN1

followed

by

immunoprecipitation

and

mass

spectrometry (MS) analysis to identify FLAG conjugated proteins. Interaction was
detected for proteins ESYT1 and ESYT2 (calcium-mediated intrinsic membrane
proteins), IGF1R, IGF2R and INSR (receptor tyrosine kinases) and BAT3/BAG6
proteins (a cytosolic multi-protein complex involved in the post-translational
delivery of tail-anchored membrane proteins to the endoplasmic reticulum
membrane) (Figure 8.1, Previous Work). We confirmed the interaction
between

UBQLN1

immunoprecipitated

and

IGF1R

FLAG-tagged

by

Western

UBQLN1

in

Blot

analysis

HEK-293T

conditions of complete media with vehicle (DMSO),

cells

of
in

proteasomal

inhibitor MG132 and serum starvation for 12 hours (Fi gure 8.2,
Previous Work). UBQLN1 interacted with IGF1R in all 3 conditions.
However, an increased interaction was detected when the proteasome
was blocked with MG132. We then investigated if interaction of
UBQLN1 with IGF1R was a phenomenon applicable to o ther receptor
tyrosine kinases and performed similar experiments to pull down FLAG
conjugated proteins in 293T cells and probed for other RTKs by
Western Blot analysis. We found that insulin receptor (INSR), a protein
60% homologous to IGF1R also interacts with UBQLN1 but EGFR
exhibited a weak, almost no interaction with UBQLN1 (Figure 8.3).
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Unique Peptide Count
MIG

Gene Name

UBQLN1
48

ESYT1

34

BAT3/BAG6

30

ESYT2

26

UBQLN1

22

IGF2R

10

IGF1R

10

SELS

8

UBLA

8

INSR

Figure 8.1: Immunoprecipitation/Mass Spectrometry Data
HEK-293T cells were transfected with FLAG epitope-tagged UBQLN1
followed by immunoprecipitation and mass spectrometry (MS)
analysis to identify FLAG conjugated proteins. MIG is the empty
vector used as a control for overexpression. These proteins are some
of the top interacting partners of UBQLN1. The strongest interaction
was detected for ESYT1, then BAT3/BAG6 and so on. Receptor
Tyrosine Kinases IGF2R, IGF1R and INSR interact with UBQLN1.
Larger number indicates stronger interaction.
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Figure 8.2: UBQLN1 interacts with IGF1R (Previous work)
HEK-293T cells were transfected with either empty vector (control) or
FLAG-epitope tagged UBQLN1 (FLAG-UBQLN1) followed by
immunoprecipitation and Western Blot analysis to detect interaction
between UBQLN1 and IGF1R. Post transfection, cells were cultured
in 3 conditions: complete media with vehicle (DMSO), proteasomal
inhibitor MG132 and serum starvation for 12 hours. UBQLN1 interacts
with IGF1R in all 3 conditions. An increased interaction was detected
when the proteasome was blocked with MG132.
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Figure 8.3: UBQLN1 interacts with IGF1R and INSR
HEK-293T cells were transfected with either empty vector
(control) or FLAG-epitope tagged UBQLN1 (FLAG-UBQLN1)
followed by immunoprecipitation and Western Blot analysis.
UBQLN1 interacts with IGF1R and INSR, confirming the
IP/MS data in Figures 8.1 and 8.2 but only weakly interacts
with EGFR.
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Cancer Mutants of UBQLN1 may lose interaction with IGF1R (Figure 9)
HEK-293T cells were transfected with FLAG-epitope tagged constructs of
mutants of UBQLN1 found in lung adenocarcinomas to test for an alteration in
ability of these mutations to interact with IGF1R (Figure 9). Eight constructs were
chosen from different domains of wild type UBQLN1 protein. P44Q and I84F are
mutations found in the UBL domain; Q174X, Y276D, A286T, Q433H, R313S are
mutations found in the STI domains while R562S are mutations found in the UBA
domain of UBQLN1. Post transfection, all mutants showed stable expression of
the FLAG-tagged constructs. Wild type UBQLN1 interacts with IGF1R as also
seen in previous figures, however some mutations cause a loss of this
interaction. Mutations in the UBL domain (P44Q, I84F), UBA domain (R562S)
and a nonsense mutation in the first STI domain (Q174X) lead to a loss of
interaction with IGF1R.
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Figure 9: Cancer mutants of UBQLN1 lose interaction
with IGF1R
HEK-293T cells were transfected with FLAG-epitope
tagged constructs of mutants of UBQLN1 followed by
immunoprecipitation and Western Blot analysis. P44Q and
I84F are mutations found in the UBL domain; Q174X,
Y276D, A286T, Q433H, R313S are mutations found in the
STI domains while R562S mutation is found in the UBA
domain of UBQLN1. While all transfected mutant
constructs stably express in these cells, mutations in the
UBL domain (P44Q, I84F), UBA domain (R562S) and a
nonsense mutation in the first STI domain (Q174X) lead to
a loss of interaction with IGF1R.
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UBQLN1 loss decreases IGF1R protein level expression (Figure 10)
Following confirmation of interaction between UBQLN1 and IGF1R, steady state
expression of IGF1R were tested in lung adenocarcinoma cell lines A549 and
H358 and also in HPL1D lung epithelial cells. UBQLN1 protein expression was
downregulated using 2 different siRNAs for UBQLN1 (siU1 and siU1_2) (Figure
10). A549 cells were cultured in 3 different conditions: complete media, serum
starvation for 12 hours and stimulation by ligand IGF1 (6h) following 12 hours of
serum starvation. Cycloheximide (20uM) was added to cells in all 3 conditions to
prevent new protein synthesis. Post treatment, cells were harvested, lysed and
analyzed by Western Blot for total and phosphorylated receptor (IGF1R or
EGFR) expression levels. While the total IGF1R expression was decreased in
UBQLN1 deficient cells in all 3 conditions as seen in Figure 10.1, differences
were glaringly evident in post stimulation conditions for both receptors.
Phosphorylated IGF1R levels were undetectable in A549 cells in complete and
serum deficient media, however post stimulation with IGF1, the ratio of
phosphorylated to total IGF1R levels was greatly increased in siUBQLN1 cells
(1.46 vs. 1.05) compared to control. Results are normalized to non-treated
control in complete media. In H358 cells exposed to conditions of serum
starvation and IGF1 stimulation, phosphorylated/total IGF1R is higher in siU1
cells compared to siNT cells (Figure 10.2). We detected phosphorylated IGF1R
even in serum starved siU1 cells but absent in control. Similar results were
observed in IGF1 stimulated HPL1D cells (Figure 10.2).
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Figure 10.1: Loss of UBQLN1 decreases total IGF1R expression in
A549 cells
A549 cells were transfected with siRNA (NT: non targeting control, U1
and U1_2: UBQLN1) and post transfection, cultured in 3 different
conditions in the presence of cycloheximide (translation inhibitor):
Complete media, Serum Starvation (SS) or stimulation with IGF1 for 6
hours, post 12 hours of serum starvation. Total IGF1R levels were
decreased in UBQLN1 knock down cells and results are more
pronounced post stimulation with IGF1. Phosphorylated IGF1R levels
were undetectable in A549 cells in complete and serum deficient
media, however post stimulation with IGF1, the ratio of phosphorylated
to total IGF1R levels was greatly increased in siUBQLN1 cells (1.46,
2.10 vs. 1.05) compared to control.

29

Figure 10.2: Loss of UBQLN1 decreases total IGF1R expression in H358
and HPL1D cells
H358 cells were transfected with siRNA (NT: non targeting control, U1:
UBQLN1) and post transfection, cultured in 2 different conditions in the
presence of cycloheximide (translation inhibitor): Serum Starvation (SS) or
stimulation with IGF1 for 6 hours, post 12 hours of serum starvation. Total
IGF1R levels were decreased in UBQLN1 knock down cells. There is
increased expression of phosphorylated IGF1R in UBQLN1 knock down
cells in serum starved cells as well as post stimulation with IGF1. Similarly,
in lung epithelial cell line HPL1D, following siRNA transfection, total receptor
levels were decreased, but there is an increase in phosphorylated IGF1R
expression.
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Loss of UBQLN1 results in decreased cell surface expression of IGF1R
(Figure 11)
Following Western Blot data that showed decreased total IGF1R expression in
cells, saturation binding assays were performed to test if the overall decrease in
total IGF1R expression also reflected as a decrease in receptor number on the
cell surface. Radioligand binding assays were performed utilizing radioactive
ligand (I125-IGF1) to test for differences in the number of binding sites (number of
cell surface receptors) in HPL1D cells between UBQLN1 deficient cells and
control (Figure 9). In these experiments, HPL1D cells were transfected with
UBQLN1 siRNA (siU1) or control (siNT) and 48 hours post-transfection, cells
were incubated with increasing concentrations of the radiolabeled ligand (I125IGF1) with the intention to saturate the receptors. The purpose of performing
saturation binding assays was to determine the differences in maximum binding
capacity Bmax (number of cell surface receptors) between UBQLN1 deficient cells
and control. Plotting saturation curves showed that although the amount of
radioactive ligand used did not saturate the receptors, the total binding activities
for I125-IGF1 were considerably lower in cells with loss of UBQLN1 compared to
control (Figures 11.1). Scatchard plot analysis suggests that IGF1 receptors
exhibit properties of positive cooperativity i.e. binding of ligand to one site
increases the affinity at other binding sites. Overall, Bmax or number of cell
surface IGF1 receptors was 2-fold lower in UBQLN1 deficient cells while the Kd
-10

i.e. affinity is almost the same (0.4 x 10

are representative of 3 independent experiments.
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-10

M vs. 0.6 x 10

M) (Figure 11.2). Data

Figure 11.1: Saturation binding of I125-IGF1 in HPL1D cells
HPL1D cells were transfected with UBQLN1 siRNA (siU1) or control
(siNT) and 48 hours post-transfection, cells were incubated with 7
increasing concentrations of the radiolabeled ligand I125-IGF1 (counts per
minute, CPM added) and cells were processed after 2-hour incubation to
determine the amount of radioligand bound to the cell surface receptors
(CPM bound). Plotting saturation curves showed that the total binding
activities for I125-IGF1 were considerably lower in cells with loss of
UBQLN1 (siU1) compared to control (siNT). Total: Total binding of I125IGF1 to cell surface proteins. Non-Specific: Binding of I125-IGF1 to cell
surface proteins other than IGF1R. Specific: Binding of I125-IGF1 to
IGF1R and is calculated by subtracting Non-Specific CPM from Total
CPM for each dose of I125-IGF1. Radioactivity was measured as CPM in
a Beckman gamma counter (efficiency=0.45). Specific activity of I 125IGF1 = 2200 Ci/mmol.
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Figure 11.2: Scatchard plot analysis
Scatchard plots were graphed using binding data to determine the number
of ligand-binding sites (Bmax) on the cell surface and to calculate ligand
affinity (Kd) for IGF1R. Data are plotted as bound receptors versus
bound/free receptors. Scatchard plot for IGF1R exhibits positive
cooperativity for I125-IGF1. The table represents the differences in Bmax in
HPL1D cells that have loss of UBQLN1. There were fewer binding sites on
surface of UBQLN1 deficient cells while the Kd remained constant.
Radioactivity was measured as counts per minute (CPM) in a Beckman
gamma counter (efficiency=0.45). Specific activity of I 125-IGF1 = 2200
Ci/mmol.
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Immunofluorescence (Figure 12)
Confocal microscopy imaging was performed to test for any gross detectable
changes in overall expression of IGF1R between UBQLN1 deficient cells and
control. Figure 12.1 demonstrates confirmation of UBQLN1 knock down using
siU1 in HPL1D cells. HPL1D, A549 and H358 cells were transfected with siRNA
(siUBQLN1 and siNT) and 48 hours post-transfection, cells were fixed and
permeabilized and probed with indirect fluorescence targeting β-IGF1R in these
cells. Overall, IGF1R expression was higher in lung adenocarcinoma cell lines
A549 and H358 (Figure 12.3) compared to lung epithelial cell line HPL1D (Figure
12.2). In HPL1D cells, we observed slight decrease in cell surface expression of
IGF1R in siUBQLN1 cells compared to control.
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Figure 3: Immunofluorescence imaging of UBQLN1

Figure 12.1: Confocal microscopy image of UBQLN1
Cells were incubated overnight in complete media at 4C with primary
antibody against UBQLN1. Alexa 488- conjugated secondary antibody was
used for indirect fluorescence detection. DRAQ5 was used to stain nuclei
and Phalloidin was used for staining of cytoskeletal β-Actin. HPL1D cells
with siRNA against UBQLN1 clearly show a decreased signal for UBQLN1
staining. The images were captured using Nikon A1R confocal microscope.
The scale represents 20µM.
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Figure 12.2: Immunofluorescence imaging of β-IGF1R in lung epithelial
cell line.
Cells were incubated overnight in complete media at 4C with primary
antibody against β-IGF1R. Alexa 488- conjugated secondary antibody was
used for indirect fluorescence detection. DRAQ5 was used to stain nuclei and
Phalloidin was used for staining of cytoskeletal β-Actin. In HPL1D cells, there
clearly appears to be lower expression of IGF1R on the plasma membrane of
cells that have loss of UBQLN1 (siU1) compared to control. The images were
captured using Nikon A1R confocal microscope. The scale represents 20µM.
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Figure 12.3: Immunofluorescence imaging of β-IGF1R in hLAC cell
lines.
Cells were incubated overnight in complete media at 4C with primary
antibody against β-IGF1R. Alexa 488- conjugated secondary antibody was
used for indirect fluorescence detection. DRAQ5 was used to stain nuclei
and Phalloidin was used for staining of cytoskeletal β-Actin. Overall, there is
higher expression of IGF1R in hLAC cells (A549, H358) than lung epithelial
cells (HPL1D) but there are no grossly detectable differences in its
expression in UBQLN1 deficient cells (siU1). The images were captured
using Nikon A1R confocal microscope. The scale represents 20µM.
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Loss UBQLN1 leads to decreased IGF1R and EGFR mRNA levels in
A549 cells (Figure 13)
Quantitative real-time PCR (qRT-PCR) were performed in A549 cells to
test for relative mRNA levels of IGF1R an d EGFR in cells that have
siRNA mediated loss of UBQLN1 (Figure 13). Results were normalized
to housekeeping gene human beta-2-microglobulin. We found a 2-fold
decrease in IGF1R mRNA levels (p=0.0015 , SEM=0.04 for siUBQLN1,
p=0.0094, SEM=0.06 for siUBQLN1-2) and almost 30% decrease in
EGFR mRNA levels (p=0.0261, SEM=0.08 for siUBQLN1) in UBQLN1
deficient cells. Data are representative of 3 independent experiments
done in triplicates.
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Figure 13: Relative mRNA levels of IGF1R and EGFR in
A549 cells
A549 cells were transfected with siRNA (siNT: control, siU1,
siU1_2: UBQLN1) and cultured in complete media. 48 hours
post transfection, qRT-PCR was performed. A 50% decrease in
IGF1R mRNA levels (*p=0.0015, SEM=0.04 for siUBQLN1 ,
#p=0.0094, SEM=0.06 for siUBQLN1-2) and almost 30%
decrease in EGFR mRNA levels (*p=0.0261, SEM=0.08 for
siUBQLN1) in UBQLN1 deficient cells.
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Loss of UBQLN1 affects degradation of RTKs (Figure 14)
These set of experiments were performed to test for role of UBQLN1 in
degradation of IGF1R and EGFR. A549 cells were transfected with respective
siRNA (siUBQLN1 or siNT) (Figure 14). 48 hours post-transfection, cells were
incubated with either a proteasomal (MG132) or lysosomal inhibitor (NH4Cl) or
both for an hour prior to stimulation with ligand IGF1 (50ng/ml) or EGF (10ng/ml).
Therefore, in all, there were 5 experimental conditions as observed in the figure.
Cells were harvested (6 hours after IGF1 stimulation or 3 hours after EGF
stimulation) and analyzed by Western Blot. In the absence of lysosomal and
proteasomal inhibitors, our results were consistent with our previous data. In
UBQLN1 deficient cells, we observed decreased expression of total IGF1R and
EGFR while phosphorylated IGF1R and EGFR levels were increased when
stimulated with respective ligands. Presence of MG132 and NH4Cl, rescued
some amount of total receptor levels otherwise degraded in the absence of
UBQLN1 while stabilized phosphorylated IGF1R and EGFR in UBQLN1 deficient
cells compared to control. These data imply that loss of UBQLN1 accelerates
degradation of non-phosphorylated IGF1R and EGFR and therefore resulting in
higher expression of phosphorylated form of the 2 receptors. It also appears that
in A549 cells, UBQLN1 may be essential for lysosomal degradation of
phosphorylated IGF1R as loss of UBQLN1 almost completely prevents its
degradation via this pathway. Under these experimental conditions, proteasomal
and lysosomal pathways degrade EGFR equally and UBQLN1 may play an
important role in degradation of proteins via both these pathways.
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Figure 14.1: Loss of UBQLN1 affects degradation of IGF1R
These experiments were performed in A549 cells following siRNA
mediated knock down of UBQLN1 (siU1). 48 hours post siRNA
transfections; cells were exposed to 5 different conditions in the presence
of cycloheximide. Serum starvation (SS) for 12 hours, SS for 12h and
stimulation by 50ng/ml recombinant IGF1 for 6 h, addition of MG132 an
hour prior to ligand stimulation, addition of NH4Cl, a lysosomal inhibitor an
hour prior to stimulation and addition of both inhibitors. There is
decreased total IGF1R in siU1 lanes in all conditions. MG132 and NH 4Cl,
both rescue IGF1R from degradation implying that under these
experimental conditions, IGF1R is degraded via both routes. Higher
phosphorylated receptor levels are observed consistently across all siU1
cells in all conditions indicating that loss of UBQLN1 prevents
dephosphorylation of IGF1R and stabilizes the active receptor. In
addition, use of MG132 and NH4Cl further stabilize the active receptor. In
conclusion, loss of UBQLN1 accelerates degradation of nonphosphorylated IGF1R while stabilizes the phosphorylated form.
Semiquantitative densitometry analysis was performed using ImageJ
software.
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Figure 14.2: Loss of UBQLN1 affects degradation of EGFR
These experiments were performed in A549 cells following siRNA
mediated knock down of UBQLN1 (siU1). 48 hours post siRNA
transfections; cells were exposed to 5 different conditions in the
presence of cycloheximide. Serum starvation (SS) for 12 hours, SS for
12h and stimulation by 50ng/ml recombinant EGF for 3 hours, addition
of MG132 an hour prior to ligand stimulation, addition of NH4Cl, a
lysosomal inhibitor an hour prior to stimulation and addition of both
inhibitors. There is decreased total EGFR in siU1 lanes in all conditions.
MG132 and NH4Cl, both rescue EGFR from degradation implying that
under these experimental conditions, EGFR is degraded via both
routes. Higher phosphorylated receptor levels are observed consistently
across all siU1 cells in all conditions indicating that loss of UBQLN1
prevents dephosphorylation of EGFR and stabilizes the active receptor.
In addition, use of MG132 and NH4Cl further stabilize the active
receptor. In conclusion, loss of UBQLN1 accelerates degradation of
non-phosphorylated IGF1R while stabilizes the phosphorylated form.
Semiquantitative densitometry analysis was performed using ImageJ
software.
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IGF1R degradation assay (Figure 15)
Our data showed that UBQLN1 regulates steady state expression and
degradation of IGF1R and EGFR. UBQLN1 deficient cells have lower mRNA and
protein levels of IGF1R and EGFR, but higher expression of phosphorylated form
of the receptor 6 and 3 hours post stimulation with ligand. To test if the increased
expression phosphorylated receptor was sustained at longer time points, a
degradation assay of the receptor was performed. In this experiment, A549 cells
were cultured in complete media and transfected with siRNA for UBQLN1 or
control. Cycloheximide (20uM) was added to the media to prevent biosynthesis
of new protein levels. The ligand IGF1 (50ng/ml) was spiked into the serum free
media after 60 minutes exposure of cells to cycloheximide and followed for 5
different time points: 0h, 6h, 12h, 18h, 27h. At the end of each time point, cells
were harvested, lysed and analyzed by Western Blot to test for protein
expression. For every time point, expression of total IGF1R was decreased in
UBQLN1 deficient cells and the differences became more apparent with longer
time points. Phosphorylated receptor was detected only in IGF1 stimulated cells
with highest expression at 6h and decreased phosphorylation at longer time
points. Most importantly, phosphorylated receptor levels were detected even at
27 hours post ligand stimulation. IGF1R activation stimulates PI3K/AKT pathway
and expression of AKT was tested for effects of UBQLN1 knockdown on this
pathway. A similar trend was observed for both IGF1R and AKT proteins such
that total protein level expression in UBQLN1 deficient cells were decreased
while the phosphorylated protein levels were increased at 0h in absence of IGF1

43

stimulation and differences in protein expression were more pronounced post
ligand stimulation even at 27 hours. In conclusion, IGF1R protein was not fully
degraded even at the longest time point chosen for this experiment (27 hours).
However,

IGF1R

half-life

studies

have

not

been

published

in

lung

adenocarcinoma cell lines before and therefore this may not necessarily be an
unusual finding.
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Figure 15: IGF1R degradation assay
A549 cells were transfected with siRNA (NT: non targeting control, U1
and U1_2: UBQLN1). 48 hours post transfection, cells were serum
starved for 12 hours and exposed to translational inhibitor
cycloheximide before stimulating with ligand IGF1 and chased for the
following time points:0h, 6h, 12h, 18, 27h. Total IGF1R levels were
decreased in UBQLN1 knock down cells at all time points and results
are more pronounced at later time points. Phosphorylated IGF1R
levels were undetectable 0h without ligand stimulation and at every
other time point, in complete and serum deficient media, however post
stimulation with IGF1, the ratio of phosphorylated to total IGF1R levels
was greatly increased in siUBQLN1 cells (1.46, 2.10 vs. 1.05)
compared to control.
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CHAPTER 4: DISCUSSION
The role of Ubiquilin proteins is largely studied in the field neurodegenerative
disorders and is slowly emerging in the field of cancer. We have demonstrated
role of UBQLN1 in lung cancer and how UBQLN1 regulates expression and
activity of receptor tyrosine kinases like IGF1R and EGFR. Our lab has
previously shown that UBQLN1 is lost and under-expressed in lung
adenocarcinomas cell lines and samples [1] and cells that have loss of UBQLN1
develop clonogenic potential and migratory and invasive properties [4].

We have identified an interaction between UBQLN1 and IGF1R and INSR. Some
mutations in UBL, UBA and STI domains of UBQLN1 led to loss of interaction
with IGF1R. UBQLN1 interacts with and regulates expression and activity of
IGF1R in lung cell lines. When UBQLN1 is lost, there is decreased overall
expression of IGF1 receptors. Similarly, loss of UBQLN1 also leads to a
decrease in expression of EGFR, despite only weakly interacting with it, which
indicates that UBQLN1 regulates expression of receptor tyrosine kinases
independent of interaction. Research studying the role of UBQLN1 in receptor
trafficking have only been conducted in neurons where expression of UBQLN1
stabilizes cell surface levels of GABAA receptors [47] and upregulates nicotinic
acetylcholine receptors [20]. Radioligand binding assays confirmed that
decreased total receptor levels in UBQLN1 deficient cells also reflected as
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decreased number of cell surface IGF1R in these cells. Despite fewer receptors
being activated in UBQLN1 deficient cells, there is an increased ratio of
phosphorylated to total receptor levels. Loss of UBQLN1 leads to higher levels of
phosphorylated IGF1R, EGFR and AKT protein levels. Experiments in a lung
adenocarcinoma cell line also showed that the higher expression of active IGF1R
is also sustained at the longest time point tested–27 hours after ligand
stimulation. Decreased levels of IGF1R and EGFR in UBQLN1 deficient cells
can be a result of decreased biosynthesis of the protein or increased turnover or
a variety of post-translational modifications or a combination of all. UBQLN1
deficient A549 cells showed 50% decrease in transcript levels of IGF1R and 30%
decrease in EGFR levels demonstrating there is decreased biosynthesis of the
RTKs. One of UBQLN1’s well-known functions is facilitating degradation of
proteins [18, 27, 48] When tested for degradation of the receptor, loss of
UBQLN1 stabilized the phosphorylated receptor and accelerated degradation of
the non-phosphorylated receptor. This suggests that when UBQLN1 is present, it
directly or indirectly, mediates degradation of phosphorylated IGF1R and EGFR
and plays an important role in RTK trafficking and turnover. Mechanisms
underlying these phenomena are not currently known but we suggest that higher
levels and/or longer duration of a continuously active protein can contribute to
initiation and/or progression of transforming events in cells.
Ubiquitination is a crucial regulatory process in protein signaling and turnover.
Ubiquitination of proteins is a multi-step process such that E1 and E2 ligases
recruit protein specific E3 ligases to load ubiquitin molecules on it. Three E3
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ligases have been identified to ubiquitinate IGF1R namely Mdm2[38], Nedd4[39],
and c-Cbl[40]. Mdm2 mono-ubiquitinates IGF1R at multiple sites on the receptor,
Nedd4 polyubiquitinates with K63 type chains and c-Cbl polyubiquitinates with
K48 type chains. K48 poly-ubiquitination signals proteins towards the
proteasome for degradation while K63 mono- and poly-ubiquitination signals for
interactions with proteins for other cellular processes [30]. Normally, activated
IGF1R

and

EGFR

are

internalized

by

endocytosis

and

subsequently

downregulated by lysosomes or ubiquitin-proteasome system or recycled back to
the plasma membrane thus tightly regulating the duration and intensity of
downstream signaling events [37]. Studies have shown that mutations in proteins
(ex: c-Cbl) that control RTK (ex: c-MET) trafficking and turnover can cause this
regulation to be lost such that it leads to persistent activity of the receptor even in
the absence of receptor overexpression or activating oncogenic mutations [49].
Based on data on UBQLN1’s interaction with ubiquitinated proteins [6, 18], it is
most likely that UBQLN1 acts as an adaptor protein aiding in ubiquitination of the
phosphorylated receptor. There is no data currently on whether Ubiquilin1 binds
E3 ligases. However, UBQLN1 binds ubiquitin through its UBA domain and may
control type of ubiquitination in coordination with other proteins. As stabilization
of the phosphorylated RTK is a hallmark finding of loss of UBQLN1 in lung
cancer cell lines, we hypothesize that normally UBQLN1 facilitates K48 polyubiquitination of non-phosphorylated receptor and signals for its degradation. In
absence of UBQLN1, the phosphorylated RTK is unable to get degraded leading
to its stabilization and continuous stimulation of downstream signaling pathways.

48

An alternate theory is that UBQLN1 may be required for normal activity of
phosphatases that act on RTK’s. Timely downregulation of phosphorylated
IGF1R and EGFR may be delayed in absence of UBQLN1, leading to stabilized
activity of the phosphorylated RTK. The phosphatase protein PTP1B negatively
regulates IGF1R phosphorylation in a ligand dependent manner[50]. Another
phosphatase SHP2 associates simultaneously with phospho-tyrosines on IGF1R
and SH2 domains and directly dephosphorylates IGF1R. An adaptor protein,
SHPS2 is critical for recruitment of the phosphatase to the plasma membrane.
An integrin protein αVβ3 acts via this phosphatase SHP2 to decrease
phosphorylation of IGF1R [51]. Ubiquilin1 was originally discovered as an integrin
associated protein [2] and through its action on integrins may control SHP2
phosphatases activity.
Overall, UBQLN1 regulates activity of IGF1R and EGFR and in cancers that have
loss of UBQLN1, dysregulation of this activity may contribute to initiation and
progression of tumorigenesis and it may also contribute to other pathologies
associated with RTK aberrations. While RTK’s has been shown to be a logical
and valid target for many cancers including lung adenocarcinoma, targeting
these receptors has not proven to be very successful in the long run. Possible
reasons for failure include the complexity of the RTK system, parallel growth and
survival pathways and lack of patient selection biomarkers. A variety of
mechanisms may confer intrinsic or acquired resistance, highlighting the need for
understanding the regulation of IGF1R in greater detail. Regulation of activity of
receptors after ligand binding/activation can often be overlooked when
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developing therapeutics against targeted receptor. We have observed that
UQBLN1 regulates IGF1R activity such that lung adenocarcinoma cell lines that
have loss of UBQLN1 have higher activity of the RTK. UBQLN1 loss in tumors
can act as a biomarker for patient selection for treating with receptor tyrosine
kinase pathway inhibitors. In conclusion, UBQLN1 plays a role in regulating RTK
expression and activity and studying its mechanism of action is warranted and
promising as a novel therapeutic approach in pathologies involving receptor
tyrosine kinases.
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